Business Context and Reporting Period
This Form 8-K Current Report was filed by Prelude Therapeutics Inc. (PRLD) on October 15, 2025, covering events occurring on October 15 and October 17, 2025. The filing addresses changes to the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Director Resignation: Mardi Dier, a Class III member of the Board of Directors, resigned effective October 17, 2025. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Director Appointment: Katina Dorton, J.D., MBA, was appointed as a Class III director effective October 17, 2025. She will serve until the 2026 Annual Meeting of Stockholders.
- Committee Assignments: Ms. Dorton was appointed as a member of the Audit Committee and will serve as Chair of the Audit Committee.
Guidance, Outlook, and Compensation
The filing contains no financial guidance, outlook, or management commentary regarding business operations. Regarding compensation for the new appointment:
- Ms. Dorton will receive standard non-employee director compensation.
- The Board granted Ms. Dorton non-incentive stock options to purchase up to 76,000 shares of common stock under the 2020 Equity Incentive Plan.
- Options vest over a three-year period (1/36th per month), subject to continued service.
- An indemnity agreement will be executed in the standard form used for other directors.
Investor Verification Checklist
- Verify the effective date of Mardi Dier's resignation and Katina Dorton's appointment (October 17, 2025).
- Confirm the number of stock options granted to Ms. Dorton (76,000 shares) and the vesting schedule.
- Review Ms. Dorton's background, including her prior roles as CFO of NodThera and current board seats at Fulcrum Therapeutics and TScan Therapeutics.
- Check for any undisclosed related party transactions involving Ms. Dorton (none were disclosed in this filing).